Orchid Pharma Limited — Others, 25-05-2025: Shareholders meeting

Orchid Pharma has announced a board meeting to approve the Scheme of Amalgamation with its unlisted subsidiary, Dhanuka Laboratories Limited (DLL). The merger will issue Orchid shares to DLL shareholders at a 161:5 ratio, increasing Orchid’s authorized capital to INR 164.51 Cr and paid-up capital to INR 59.88 Cr, with promoter holding rising to about 74.45%. This move aims to streamline management, leverage synergies in API manufacturing, and strengthen the balance sheet. DLL operates cephalosporin and non-cephalosporin API facilities serving domestic and international markets. The combined entity expects improved competitive positioning and enhanced revenue capacity.